Importantly, the therapeutic window for NRF2 modulation appears most advantageous during the early-to-mid stages of CKD and in the initial phase of fibrotic remodeling, where boosting antioxidant defenses may attenuate oxidative damage and favorably alter disease trajectory. Here, NFE2L2 is linked to chronic kidney disease.